Novarad Selects Glassware 2.0 Virtualization Platform from Sphere 3D
Collaboration agreement will allow for the delivery of performance enhancements, new IaaS capabilities, and Windows XP migration
Mississauga, Ontario--(Newsfile Corp. - April 24, 2014) - Sphere 3D Corporation (TSXV: ANY) (OTCQX: SPIHF), a virtualization technology solution provider and Novarad Corporation, supplier of one of the top 3 rated PACS (Picture Archiving and Communication System) in America, announced today that they have entered into a collaboration agreement for the utilization of Glassware 2.0™ as infrastructure for the delivery of next generation Radiology Software.
"We have tested many of today's leading virtualization technologies and have looked at a number of potential solutions; none were able to deliver the simple migration to virtualization and incredible performance that we get from the Sphere 3D approach to virtual computing." said Paul Shumway, Senior Vice President of Novarad, "The first time we saw our products run on Glassware 2.0, we were sold ".
Well, despite the hit piece the stock continues to climb.
Look at the trading pattern as well: down in the am and then finishing strong at the end, a classic short covering tactic. One piece of good news and it's lights out for the shorts, but never underestimate their firepower or determination.
This looks to be a great company in the making. Need one more big player to sign on in addition to Dell and I think the short case is over and done with. If things continue the way they have been it's only a matter of time.
Viscount Systems Appoints Michael Pilato as V.P., Sales & MarketingSenior Sales Executive with 25 Years Experience in Blue Chip Companies
(Burnaby, BC, April 21, 2014) -- Viscount Systems Inc. (OTCQB:VSYS), a leading-edge supplier of security systems and software, is pleased to announce the appointment of Michael Pilato to the position of Vice President of Sales and Marketing. In this leadership role, Mr. Pilato will be responsible for managing product strategy, building the Viscount brand and driving revenue for Viscount product lines through all channels globally.
Mr. Pilato is an experienced C-level Marketing and Business Development executive with 25 years of experience in software and Physical Security related industries. He has managed international businesses and sales channels on five continents, working in senior sales & marketing roles at blue chip companies such as Schlage/Ingersoll Rand, Assa Abloy, Honeywell Security, and Sensormatic/Software House (now Tyco). He has successfully started new business enterprises and launched innovative new products in Access Control, Identity Management, SaaS/Cloud Services, and PSIM.
“The appointment of Michael to the executive team fills a critical sales role for our Freedom cyber secure access control technology, which continues to gain market share, and our legacy intercom systems business,” stated Dennis Raefield, Viscount Systems’ President and CEO. “Michael brings strong operational experience and deep domain expertise which will help us to scale and compete more effectively in the global marketplace. He is unique in that he has successfully started and run new business enterprises both within large corporate structures and in venture-backed start-ups. Michael has a proven record of team-building and delivering results in both early stage as well as mature businesses.”
That's not an ignorant question at all.
If I remember correctly, a couple of years ago when the trial was getting going I asked the same question and the response was that around 2/3 of patients were thought to have leaky vessels. Now I'm not sure how they came up with this number, or if my memory of the conversation is 'exact', but that's been my supposition for some time now.
So the odds are still good that the 398 trial will work, but as in all trials we'll just have to wait and see. I am told that the Brean note said that they STILL don't have 305 deaths, the 'trigger' number to unblind the trial, and that is of course also in our favor.
He doesn't know anything at all. There is the annual meeting on Saturday, that is all. There will be an update on the MSA situation(approval of Naasco purchase) and other than that just a general summary of events we all know about.
This is a great long term investment, but the short term value will be dependent on getting approval to market their premium brand cigarettes. That will probably come sometime in the next month, and when it does we have a commercial stage company with distributors already lined up.
Just reviewed the MM398 poster and have a few comments.
First of all, it's a small study, only 12 people and 9 of whom had data that was evaluable for this poster. So take everything with a bit of a grain of salt.
That said, it appears that the imaging agent can accurately predict the amount of MM398 that will get into the tumor, and if that amount is over the mean(average), that the tumor is more likely than not going to shrink considerably. In other words, in patients who have leaky enough vasculature for MM398 to enter tumors MM398 appears to work well. In the other group of patients where 398 does not get in, the drug does not have much effect. Kind of obvious, all this, but having an agent that is predictive is very powerful stuff.
There is no use in parsing the numbers too carefully because there are too few patients, but the study appears to accurately predict exactly in whom MM398 will work, and that is obviously important. Any future trial with 398 or other liposomal agents(302, etc.) will hopefully utilize this technology as a screening tool which will increase the odds of success very significantly. The current 398 trial did not employ a diagnostic imaging agent.
Well, that's a relief. She was one angry analyst. I'm not sure what caused her to be so unpleasant and almost accusatory on her phone calls with MACK, but I for one am not sad to see her go.
It does seem unusual for them to pull coverage just because one analyst left. Usually there are others working on the same company so the coverage stays. Sounds like there is another story beneath the headlines, but one we'll probably never know.
There is a new management team in place. I understand your frustration with the history of this company, and don't blame you for being cynical. But the BOD has fired the CEO and it's a new day. The new CEO is a seasoned and honest executive with a great track record. It would be a good idea to stick around and keep an eye on this. It's a classic turnaround.
Despite today's announcement of the Dell partnership the market cap is still sub $200M. With a float less than 20M shares this stock has all sorts of room to run. Todays' bump is possibly just the beginning of a nice long ride to a new level.
Well, I for one will take the opposite bet.
If 398 works, and we'll know soon enough, the 20+M shorts will have a lot of 'splainin to do, Lucy. You'll see a minimum of a 50% increase in the stock, and probably something closer to 100%. And fold in good news on 121 and a decent BD deal and this could be in the twenties easy.
So good luck, and hope you find meaning in shorting down novel technologies in an effort to save lives. Your cynicism is beyond imagining.
Today the company announced that they have partnered their Glassware technology with Dell Healthcare.
Folks, it doesn't get much better than this on the validation front. Read the link:
This puts the company in a whole new level. The deal with Dell is what many investors were waiting for before plunging in. Now the technology can be considered officially vetted and hopefully this is the first of many such announcements of this type.
Sure, I think I can help.
There are three short to intermediate term catalysts of importance here:
1. Results of the MM 398 trial in Pancreatic Cancer.
The announcement of trial results has been delayed twice so the odds of a favorable result have gone up. The longer it takes the more likely the drug works. Not a slam dunk but looking very promising. Expect results in the next month or two.
2. MM 121 for Breast and Ovarian Cancer moving into Phase III with Sanofi.
Sanofi has certainly taken their time announcing a Phase III trial but given the positive results last fall in the two Phase II trials it would be surprising to see them pass. Expect news in the next couple to three months. But could happen anytime.
3. Business Deal
Company has said publicly that they will sign a major collaboration this year. Expect substantial up front pay
ment and milestones. When will this happen? Have no clue, but hopefully soon.
Of all three the 398 results are probably the most important in the short term. Despite this drug not being part of the 'core' MACK platform, it is the first one to near commercialization. As soon as MACK becomes a commercial effort it will be significantly revalued.
As many of you know, OVRL's has partnered with Sphere 3D to make a cloud based solution for data storage and facilitate interactivity between various generations of hardware and software. It's all cloud based and sounded great but was not otherwise validated until…TODAY.
Sphere announced that they have signed a deal with Dell today to be integrated into their Healthcare platform. As Dell is a leading presence in the Healthcare space, you couldn't ask for a more important validation.
Now it's time to reconsider the implications of OVRL's relationship with Sphere. Valuable? It's your call.
Sales are what will drive the price.
As you may know already, the new product line(two tiers of the same product, which the CEO calls 'best in class') had increases of 270% last year. That is with NO added sales people. Now two new regional managers have been hired, both very experienced, and Microsoft has included VSYS in their 'recommended' companies group and is sending them qualified referrals.
So the events that will drive the stock price are new contract wins. The CEO stated on the call that anything of significance(over $50K) would probably warrant a press release. He's very interested in being transparent with investors, and has a LONG history of managing sales growth for Honeywell, Pinkerton, etc.
The company is very undervalued in my opinion, and there is much investor fatigue from the long term holders. But what I think they are underweighting is the fundamental change the new CEO has brought.
Agree. The management here gets an A+ so far for meeting their deadlines and doing the 'right' thing by investors. Many of us will be attending the annual meeting on the 12th so there will be much more to report then. Suffice it to say we wouldn't be making the trip if we didn't think it was going to be worthwhile.
Fundraise done, $2.5M in the bank, hiring 2 new regional sales managers, solid contracts with Homeland Security, new leads coming in via relationship with Microsoft where they are a 'featured' company, sales in new product line grew 270% last year and each quarter as well. CEO on the record as saying this is the best new product he's seen in years and feels this is an ideal time to be introducing it into the marketplace.
Too bad more folks don't know about this one yet. It's really a great opportunity. Dennis Raefield has a history of success as long as your arm. His arrival as CEO is a game changer.
Listen for yourself to hear how sales of the new line of security devices are growing quarter by quarter. Sales expected overall to double this year and next. I think this is a grossly undervalued opportunity but please take a look and see for yourself. The call is at 4:30PM today, and the number is: +1 (213) 493-0014.